Wen Shuang, Liu Tianqing, Zhang Hongshuo, Zhou Xu, Jin Huidan, Sun Man, Yun Zhifei, Luo Hong, Ni Ze, Zhao Rui, Fan Bo
Department of Pathology, Dalian Friendship Hospital, Dalian, China.
Department of Biochemistry, Institute of Glycobiology, Dalian Medical University, Dalian, China.
Front Oncol. 2021 Jan 8;10:609839. doi: 10.3389/fonc.2020.609839. eCollection 2020.
Low-grade B cell lymphomas of mucosa-associated lymphoid tissue (MALT) lymphomas involving the kidney were extremely rare, genetic alteration or molecular features was not yet explored, which may lead to limited choices for postoperative adjuvant or targeted. Whole-exome sequencing based tumor mutation profiling was performed on the tumor sample from a 77-year-old female presenting with discomfort at the waist was pathologically diagnosed as MALT lymphomas in the right kidney. We identified 101 somatic SNVs, and the majority of the identified SNVs were located in CDS and intronic regions. A total of 190 gain counts of CNVs with a total size of 488,744,073 was also investigated. After filtering with the CGC database, seven predisposing genes (ARID4A, COL2A1, FANCL, ABL2, HSP90AB1, FANCA, and DIS3) were found in renal MALT specimen. Furthermore, we compared somatic variation with known driver genes and validated three mutational driver genes including ACSL3, PHOX2B, and ADCY1. Sanger sequencing of germline DNA revealed the presence of a mutant base T of PHOX2B and a mutant base C of ADCY1 in the sequence, which were discovered for the first time in MALT lymphomas involving the kidney. Moreover, immunohistochemical analysis revealed that tumor cells were positive for CD20, CD79a, PAX5, CD21, and CD23, and expression of CD3, CD5, and CD8 were observed in reactive T lymphocytes surrounding tumor cells. These findings illustrated that concurrent aberrant PHOX2B and ADCY1 signaling may be a catastrophic event resulting in disease progression and inhibition of the putative driver mutations may be alternative adjuvant therapy for MALT lymphoma in the kidney which warrants further clinical investigation.
累及肾脏的黏膜相关淋巴组织(MALT)淋巴瘤的低级别B细胞淋巴瘤极为罕见,尚未探索其基因改变或分子特征,这可能导致术后辅助治疗或靶向治疗的选择有限。对一名77岁因腰部不适就诊的女性患者的肿瘤样本进行了基于全外显子测序的肿瘤突变分析,该患者经病理诊断为右肾MALT淋巴瘤。我们鉴定出101个体细胞单核苷酸变异(SNV),且大多数鉴定出的SNV位于编码序列(CDS)和内含子区域。还研究了总共190个拷贝数变异(CNV)增加计数,其总大小为488,744,073。在用癌症基因组图谱(CGC)数据库进行筛选后,在肾MALT标本中发现了7个易感基因(ARID4A、COL2A1、FANCL、ABL2、HSP90AB1、FANCA和DIS3)。此外,我们将体细胞变异与已知的驱动基因进行比较,并验证了3个突变驱动基因,包括ACSL3、PHOX2B和ADCY1。种系DNA的桑格测序显示,序列中存在PHOX2B的突变碱基T和ADCY1的突变碱基C,这是在累及肾脏的MALT淋巴瘤中首次发现。此外,免疫组化分析显示肿瘤细胞CD20、CD79a、PAX5、CD21和CD23呈阳性,在肿瘤细胞周围的反应性T淋巴细胞中观察到CD3、CD5和CD8的表达。这些发现表明,同时存在的PHOX2B和ADCY1信号异常可能是导致疾病进展的灾难性事件,抑制假定的驱动突变可能是肾MALT淋巴瘤的替代辅助治疗方法,这值得进一步的临床研究。